Sichenzia Ross Ference Carmel LLP Represents ThinkEquity LLC and Laidlaw & Company (UK) Ltd. in a $2.1 Million underwritten Public Offering

Press Release – New York, NY –March 1, 2024 – Sichenzia Ross Ference Carmel LLP represented ThinkEquity LLC and Laidlaw & Company (UK) Ltd. in an underwritten public offering of Oragenics Inc. (NYSE American: OGEN), a company focused on developing unique, intranasal nanoparticle pharmaceuticals for the treatment of neurological disorders. The offering consisted of 1,400,000 shares of common stock at $1.50 per share for aggregate gross proceeds of approximately $2,100,000, prior to deducting underwriting discounts and other offering expenses. In addition, the Company granted the underwriters a 45-day option to purchase up to an additional 210,000 shares of common stock. The offering closed on March 1, 2024.

The Sichenzia Ross Ference Carmel LLP team was led by partners Gregory Sichenzia, Marcelle S. Balcombe, Jeff Cahlon and Senior Paralegal, Raquel Vasquez